Singulex plans to use the investment to continue to develop its single-molecule counting technology.
The Merck KGaA subsidiary is launching the research-use only SMCxPRO later this year for protein detection using sandwich ELISAs paired with proprietary optical readout.
The firm also plans to list its cardiac troponin I assay as CE marked and plans to submit data to the FDA for clearance of its Clarity system and assay in 2018.
Singulex's CEO provided an update at the JP Morgan Healthcare conference on the firm's progress in developing its immunodiagnostics platform.
The results could have implications for the future adoption by cardiologists of high-sensitivity troponin assays currently being developed by biotech firms like Singulex and Nanosphere.
A fire at a Manchester hospital may have destroyed lab equipment and data, the Guardian reports.
Researchers generate a genetic database from skeletal remains from the 1845 Franklin Expedition to the Arctic, Live Science reports.
Researchers in China have begun another trial using CRISPR/Cas9 approaches in cancer patients, according to the Wall Street Journal.
In Science this week: human DNA found in sediments from archeological sites lacking bones, and more.